elsilimomab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

elsilimomab Usage And Synthesis

Uses

Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA)[1][2][3].

IC 50

IL-6: 1.4 nM (IC₅₀)

References

[1] Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265. DOI:10.1038/mt.2014.59
[2] Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390. DOI:10.3324/haematol.2016.145060
[3] Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. DOI:10.1016/j.jmb.2011.06.031

elsilimomab(468715-71-1)Related Product Information

• Research Grade Clivatuzumab (DHD14205)
• Nerelimomab [usan:inn]
• Adebrelimab
• Lilotomab
• Nirsevimab
• Iparomlimab
• Socazolimab
• Avizakimab
• Gremubamab
• Gancotamab